Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart imaging may sharpen risk prediction for lung blood pressure patients

NCT ID NCT07667673

Knowledge-focused Sponsor: Istanbul University - Cerrahpasa Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 18, 2026 · Updated 1 time

Summary

This study looks at whether detailed heart scans (echocardiograms and MRIs) can improve how doctors predict short-term risks in people with a type of high blood pressure in the lungs (pulmonary arterial hypertension). Researchers will follow 50 adults for 6 months to see if adding scan results to standard risk tools changes risk ratings and better identifies who might get worse. The goal is to improve monitoring, not to test a new treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to better ways to identify which patients with pulmonary arterial hypertension are at highest risk of worsening, helping doctors tailor treatment more precisely.
What could go wrong
This is a small, single-center observational study, not a treatment trial. It may not prove that imaging improves outcomes, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2026

Expected to finish

May 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients with established Group 1 pulmonary arterial hypertension (PAH) undergoing routine follow-up at a specialized pulmonary hypertension center. Eligible participants will have available right heart catheterization (RHC), transthoracic echocardiography, and cardiac magnetic resonance (CMR) imaging data and will undergo prospective clinical and echocardiographic follow-up for 6 months.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 18 years or older * Diagnosis of Group 1 pulmonary arterial hypertension (PAH) according to ESC/ERS guidelines * Followed at the study center with a diagnosis of PAH * Availability of right heart catheterization (RHC) and cardiac magnetic resonance (CMR) imaging data obtained within a clinically relevant time interval * Availability of analyzable clinical, imaging, and hemodynamic data * Willingness to participate in the study and provision of written informed consent Exclusion Criteria: * Age younger than 18 years * Pulmonary hypertension groups other than Group 1 PAH (Groups 2-5 PH) * Absence of either right heart catheterization or cardiac magnetic resonance imaging data within a clinically relevant time interval * Incomplete clinical or imaging data preventing analysis * Unavailable follow-up data

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pulmonary arterial hypertension are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

pulmonary arterial hypertension pulmonary hypertension

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pulmonary arterial hypertension Pulmonary hypertension Right ventricular function

Contacts and locations

Locations

  • Istanbul University Cerrahpasa Institute of Cardiology

    Istanbul, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.